Abstract
In a recent issue of Nature Medicine, Nasr et al. show that the effectiveness of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia is independent of their ability to cause differentiation. Targeted destruction of the PML-RARalpha oncoprotein appears key to eliminating the cells from which relapse can arise.
MeSH terms
-
Animals
-
Antineoplastic Combined Chemotherapy Protocols / pharmacology
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Arsenic Trioxide
-
Arsenicals / pharmacology
-
Arsenicals / therapeutic use
-
Cell Differentiation / drug effects*
-
Humans
-
Leukemia, Promyelocytic, Acute / drug therapy*
-
Leukemia, Promyelocytic, Acute / pathology*
-
Oncogene Proteins, Fusion / metabolism*
-
Oxides / pharmacology
-
Oxides / therapeutic use
-
Tretinoin / pharmacology
-
Tretinoin / therapeutic use
Substances
-
Arsenicals
-
Oncogene Proteins, Fusion
-
Oxides
-
promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
-
Tretinoin
-
Arsenic Trioxide